New Drugs FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 8 years ago
Pharma Industry News 3 Reasons Why the Pharma Supply Chain is Ripe for Digital Transformation 8 years ago